OBJECTIVE： To observe therapeutic efficacy and safety of tegafur，gimeracil and oteracil potassium combined with oxaliplatin assisting with radiofrequency ablation （RFA） in the treatment of liver metastases after radical operation of rectal cancer. METHODS： A total of 130 patients with liver metastases after radical operation of rectal cancer were randomly divided into control group and observation group， with 65 cases in each group. After RFA one week， control group was given Oxaliplatin injection 130 mg/m2 intravenously，d1， more than 3 h. Observation group was additionally given Tegafur capsule， for consecutive 14 d， drug withdrawal of 7 d， as a treatment course. A treatment course lasted for 3 weeks， and both groups received 2 courses of treatment. Short-term efficacies of 2 groups were observed as well as complete ablation rate， local recurrence rate， survival rate and the occurrence of toxic reaction. RESULTS： The total remission rate， disease control rate， complete ablation rate， 1-year， 2-year and 3-year survival rates of observation group were significantly higher than those of control group， and local recurrence rate was significantly lower than control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of toxic reaction between 2 groups （P＞0.05）. CONCLUSIONS： Tegafur，gimeracil and oteracil potas siucn combined with oxaliplatin assisting with RFA shows significant therapeutic efficacy for liver metastase after radical operation of rectal cancer， and can significantly delay disease progression， reduce local recurrence rate and prolong survival time， and does not increase the occurrence of toxic reaction.